文献速递炎症性肠病胃肠动力与功能性疾病

基于粪便气体分析诊断肠易激综合征与活动性炎症性肠病

Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-10

该研究评估一种基于粪便气体的平台技术(OdoReader)用于诊断炎症性肠病和肠易激综合征。平台由气相色谱柱、金属氧化物气体传感器和计算机算法组成,对152例粪便样本(33例活动性炎症性肠病、50例非活动性炎症性肠病、28例肠易激综合征、41例健康对照)进行分析。采用严格验证方案,分类准确度为75%至100%;双重交叉验证后,活动性克罗恩病与肠易激综合征的准确度为87%(CI 84-89%),肠易激综合征与对照的准确度为78%(CI 76-80%)。作者结论称这是首次描述用于肠易激综合征阳性诊断及炎症性肠病诊断的研究。

要点

  • 平台技术由气相色谱柱、金属氧化物气体传感器和计算机算法组成,用于分析粪便气体。
  • 对152例样本分类准确度为75%至100%,采用留一法、10折、双重交叉验证及其蒙特卡洛变体。
  • 双重交叉验证后,活动性克罗恩病与肠易激综合征准确度为87%(CI 84-89%),肠易激综合征与对照为78%(CI 76-80%)。

核心结论

  • 这是首次描述用于肠易激综合征阳性诊断以及诊断炎症性肠病的研究。

研究设计与样本

  • 研究应用由气相色谱柱耦合金属氧化物气体传感器(OdoReader)和计算机算法组成的平台技术,对152例患者的粪便样本进行分析:33例活动性炎症性肠病、50例非活动性炎症性肠病、28例肠易激综合征、41例健康供者(对照)。

主要发现

  • 平台采用留一法交叉验证、10折交叉验证、双重交叉验证及其蒙特卡洛变体等严格验证方案,分类准确度为75%至100%。
  • 双重交叉验证后,活动性克罗恩病与肠易激综合征的准确度为87%(CI 84-89%)。
  • 双重交叉验证后,肠易激综合征与对照的准确度为78%(CI 76-80%)。
  • 这些验证方案提供了对相似人群样本外预测准确度的估计。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory bowel disease and irritable bowel syndrome may present in a similar manner. Measuring faecal calprotectin concentration is often recommended to rule out inflammatory bowel disease, however, there are no tests to positively diagnose irritable bowel syndrome and invasive tests are still used to rule out other pathologies. AIM: To investigate a platform technology for diagnosing inflammatory bowel disease and irritable bowel syndrome based on faecal gas. METHODS: The platform technology is composed of a gas chromatography column coupled to a metal oxide gas sensor (OdoReader) and a computer algorithm. The OdoReader separates the volatile compounds from faecal gas and the computer algorithm identifies resistance patterns associated with specific medical conditions and builds classification models. This platform was applied to faecal samples from 152 patients: 33 patients with active inflammatory bowel disease; 50 patients with inactive inflammatory bowel disease; 28 patients with irritable bowel syndrome and 41 healthy donors (Control). RESULTS: The platform classified samples with accuracies from 75% to 100% using rigorous validation schemes: namely leave-one-out cross-validation, 10-fold cross-validation, double cross-validation and their Monte Carlo variations. The most clinically important findings, after double cross-validation, were the accuracy of active Crohn's disease vs. irritable bowel syndrome (87%; CI 84-89%) and irritable bowel syndrome vs. controls (78%; CI 76-80%). These schemes provide an estimate of out-of-sample predictive accuracy for similar populations. CONCLUSIONS: This is the first description of an investigation for the positive diagnosis of irritable bowel syndrome, and for diagnosing inflammatory bowel disease.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Aggio RB, White P, Jayasena H, et al. Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis. Aliment Pharmacol Ther. 2016. PMID: 27862117. doi:10.1111/apt.13822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。